- $717.32m
- $569.96m
Brief: Candel Therapeutics Presents Phase 3 Clinical Trial Of Can-2409
Brief: Candel Therapeutics Extends Lease Term To Aug 31, 2029
Brief: Candel Therapeutics Q2 Net Income USD -4.796 Million
U.S. STOCKS ON THE MOVE-FedEx, Galaxy Digital, Cheniere Energy
Candel Therapeutics rises after $15 million direct stock deal
Brief: Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
Brief: Candel Therapeutics Appoints Charles Schoch As Chief Financial Officer
Brief: Candel Therapeutics Q1 Net Income USD 7.379 Million
Brief: Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treatment
Brief: Candel Therapeutics Q4 Net Income USD -14.073 Million
U.S. STOCKS ON THE MOVE-Progressive Corp, Elf Beauty, ASP Isotopes
U.S. STOCKS ON THE MOVE-Canadian Solar, Quanex Building, PENN
U.S. STOCKS ON THE MOVE-Canadian Solar, Candel Therapeutics, Upstart Holdings
U.S. STOCKS ON THE MOVE-Boeing, Broadcom, RH
Candel Therapeutics tumbles as stock offering priced at steep discount
Brief: Candel Therapeutics Prices Public Offering Of 10,000,001 Shares Of Common Stock At $6.00 Per Share
Candel Therapeutics slides after launching $80 mln stock offering
U.S. STOCKS ON THE MOVE-Gold miners, Tesla, ADM
U.S. STOCKS ON THE MOVE-Candel Therapeutics, Broadcom, Reddit